Fintech PR
Artprice: All Segments of the Art Market Are Gold Mines for Those Who Know How to Anticipate and Wait
Reading Time: 3 minutes
According to thierry Ehrmann, the found and CEO of Artprice.com, “Our clients, with Artprice, can follow artworks from one appearance at auction to another, which give them insight into how collectors anticipate the Art Market and benefit from its long-term general evolution.
When we take a look at the first quarter of 2019, for instance, we see that a large number of Fine Art auction lots have proved the extraordinary profitability of Art as an investment over the last thirty years. Of these the most spectacular was probably David Hockney’s Henry Geldzahler and Christopher Scott (1969), which fetched the quarter’s best result at over $49 million on 6 March 2019 at Christie’s London. In November 1992, the same 2×3 metre canvas had sold for $1 million.”
The price evolution of Paul Signac’s Le Port au soleil couchant proves that the best financial returns are not reserved for Post-War and Contemporary artists.
The seascape’s three appearances at auction show a constant and extremely dynamic appreciation over nearly forty years, for a historical artist whose contribution to the History of Western Art has long been recognised:
- 12 May 1980: $490,000 (Sotheby’s New York)
- 11 May 1993: $1.8 million (Sotheby’s New York)
- 27 February 2019: $26 million (Christie’s London)
Basquiat still leading
The upside on works by Jean-Michel Basquiat has been somewhat less publicized over the first part of 2019… and yet the American prodigy generated three of the ten best gains in the first quarter. On 5 March 2019 at Sotheby’s London, his 1986 canvas Apex (painted two years before his death by drug overdose) reached $10.8 million, multiplying its value by no less than 370 times since its last auction in June 1988 when it sold for just $29,400.
A pencil drawing entitled Soothsayer (1983) proves that Basquiat’s success covers all of his production. Acquired for $32,900 in June 2002, this small work sold for $997,600 on 5 March 2019, representing an average annual return on investment of +22% over the last 17 years.
Similarly, his paper collage Untitled (1987) – sold during the same session at Sotheby’s in London – confirms a very clear trend:
- on 25 March 1993 it fetched $26,700 (Christie’s London)
- on 5 March 2019 it fetched $1,321,000 (Sotheby’s London)
We have seen this kind of price metamorphosis with lots of other artists as well. The Minimalist French artist, Daniel Buren (b. 1938) is today enjoying an extraordinary price ascension that is rewarding all the collectors who anticipated the power of his art a quarter of a century ago.
His canvas Peinture acrylique blanche sur tissu rayé blanc et rouge, purchased $3,500 in 1997 at Libert-Castor in Paris, fetched $357,500 at Phillips in London on 8 March 2019.
Likewise in Asia
Hong Kong’s recent prestige sales in the wake Art Basel Hong Kong generated a number of significant revaluations that benefit Asian collectors. The biggest rise in China during Q1 2019 came from a painting by Fengmian Lin (1900-1991) titled Wisteria. Twenty-seven years ago it sold for $15,000 at Sotheby’s in New York. Since 2 April 2019, it is now worth over $1.3 million.
The return to Hong Kong of great works by Chinese Modern artists, long traded on the Western marketplaces, can have a considerable impact on their value. But the development of the Hong Kong market over the last 30 years also benefits artists who have never left Asia.
Take for example the latest result for an ink drawing by artist Yu Feian (1888-1959) entitled Parrot (1945). Purchased in Hong Kong in 1990 for $11,400, the same drawing resold for 70 times that amount in the same city (Sotheby’s) on 2 April 2019 ($787,000).
Women in vogue
The Japanese artist Yayoi Kusama also, unsurprisingly, ranks among the most impressive price accretions in Q1. Today the most successful female artist on the global Art Market, with an auction turnover exceeding $100 million in 2018 (ahead of Louise Bourgeois and Joan Mitchell), Kusama has not always had this kind of success.
In 2000, the record auction price for one of her paintings was just $80,000, whereas her Interminable Net # 4 (1959) fetched close to $8 million on 1 April at Sotheby’s Hong Kong. In terms of revaluation, her sculpture Midsummer (1983), acquired for just $7,200 at Sotheby’s in London in 2000, resold for $428,000 at the same auctioneer 19 years later.
The prize for the most unexpected price jump in Q1 2019 must surely go to 17th century Flemish artist Michaelina Wautier. Long forgotten by art historians, Wautier was ‘rediscovered’ in 2018 with a first retrospective organized at the Museum aan de Stroom and at the Rubens House in Antwerp.
The renewed attention had a profound impact on the prices of her works and her canvas A garland of flowers (1652) reached $471,000 on 30 January 2019 at Sotheby’s in New York. In 1993, the strange bouquet with a hovering dragonfly sold for just $20,000.
As Q1’s global auction results show, the best financial performances come from all segments of the Art Market, and not just from its high-end or from Contemporary Art or from the American market…
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News5 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News4 days ago
Banxso Acquires Australian ASIC License, Enhancing Its Global Trading Operations
-
Latest News5 days ago
135th Canton Fair Launches a Showcase of Innovative Products of New Collection to Lead Global Market Trends
-
Latest News5 days ago
BII and FMO back BECIS with joint US$50 million financing facility supporting commercial and industrial renewables sector in South-East Asia
-
Latest News3 days ago
BMO Announces Election of Board of Directors
-
Latest News5 days ago
Silent Eight secures AIA as its latest client
-
Latest News5 days ago
JLL Asia Pacific Awarded Frost & Sullivan’s 2023 APAC Company of the Year Award for Delivering a Broad Product Portfolio That Meets Industry Demands and Customer Expectations